肝内胆管癌外科治疗进展  

Advances in surgical treatment of intrahepatic cholangiocarcinoma

作　　者：张捷[1] 刘颖斌 ZHANG Jie;LIU Ying-bin(Department of General Surgery,Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine,Shanghai 201112,China)

机构地区：[1]上海交通大学医学院附属仁济医院南院普外科、胆胰外科,上海201112

出　　处：《中国实用外科杂志》2023年第9期1070-1076,共7页Chinese Journal of Practical Surgery

基　　金：国家自然科学基金重点项目(No.32130036)。

摘　　要：肝内胆管癌(ICC)是位于左右肝管汇合部以上的胆管上皮细胞恶性肿瘤。其在肝脏原发恶性肿瘤中发病率仅次于肝细胞癌,近年来在全球发病率都呈上升趋势。外科手术仍是目前可以使病人获得较长生存期最主要的治疗方式,但针对手术治疗中的术前黄疸的处理、肝切除范围和切缘宽度、淋巴结清扫与否等尚无统一标准。随着医学发展,肝移植、消融治疗、放化疗以及靶向免疫治疗等治疗方式为病人带来了更多生存机会。Intrahepatic cholangiocarcinoma(ICC)which is also called Intrahepatic cholangiocellular carcinoma,is a malignant tumor of bile duct epithelium above the confluence of the left and right hepatic ducts.The incidence of ICC is only second to hepatocellular carcinoma(HCC)among hepatic malignant tumors and has also significantly increased globally.At present,the surgical treatment of ICC is still the primary treatment that can cure ICC and provide a chance of long-term survival for the patients.But there are still no unified and effective standards about the disputes of preoperative jaundice management,extent of hepatectomy and the width of the surgical margin,lymph node dissection and so on.However,with the development of medical,therapys such as liver transplantation,PRFA,chemoradiotherapy,the targeted therapy and immunotherapy bring patients more chances of survival.

关 键 词：肝内胆管癌 外科手术 进展 

分 类 号：R6[医药卫生—外科学]